Scientists from the University of Washington and the US Department of Veterans Affairs wanted to know whether the risk of liver cancer increased or decreased depending on which direct-acting antiviral (DAA) regimen was prescribed to a particular patient.
It’s the latest research in a series of studies looking at the complicated issue of DAAs, HCV infection, and cancer. Hepatitis C itself is a leading cause of hepatocellular carcinoma (HCC) and other liver cancers. Moreover, HCV can cause other conditions, such as cirrhosis, which in turn increase a patient’s risk of liver cancer.
On the one hand, DAAs help patients achieve sustained virologic response, which slows the progression of cirrhosis, and thus lowers the patient’s cancer risk.